Trial intelligence / Profile preview

LIBRETTO-001 selpercatinib in RET-altered advanced solid tumors

2023-507702-13-00Phase 2Authorised

Sponsor

Loxo Oncology

Start

Sep 2017

Modality

Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Allosteric Modulators → Classical Binding Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules

Countries

16